composed of mature, long-lived B and T-cells that do not need to be regenerated by HSC.
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TIE2 1 ENDOTHELIAL CELLS MEDIATE HEMATOPOIETIC STEM CELL RE-GENERATION VIA EGF SIGNALING Doan, P.L. 1 , Russell, J.L. 1 , Himburg, H.A. 1 , Helms, K. 1 , Meadows, S.K. 1 , Daher, P. 1 , Sullivan, J.M. 2 , Jeffords, L.B. 2 , Chao, N.J. 1 , Kirsch, D.G. 2 , Chute, J.P. 1 1 Duke University Medical Center, Durham, NC; 2 Duke University Medical Center, Durham, NC Hematopoietic stem cells (HSCs) reside in anatomic association with sinusoidal vessels in the bone marrow (BM), but the mechanisms through which BM endothelial cells regulate HSC regeneration remain unknown. We measured the function of BM ECs in regulating hematopoietic regeneration after ionizing radiation by deletion of the pro-apoptotic genes, Bak and Bax, within Tie2 1 cells in Tie2Cre;Bak 2/2 ;Bax Fl/mice. Following a lethal dose of total body irradiation (TBI), these mice demonstrated protection of BM HSCs and 100% survival, whereas mice that retained Bax expression in Tie2 1 cells demonstrated depletion of BM HSCs and only 10% survival (p \ 0.0001). Chimeric mice which lacked Bak and Bax in BM HSCs but retained Bak and Bax in BM ECs demonstrated an intermediate phenotype (42% survival), indicating that the intrinsic pathway of apoptosis regulates HSC survival from radiation in an HSC-autonomous manner and via an EC-dependent mechanism.
To determine the mechanism through which Tie2 1 BM ECs regulate HSC regeneration, we generated primary BM EC lines from Tie2Cre;Bak 2/2 ;Bax Fl/mice (Bax 2/2 BM ECs) and Tie2Cre;Bak 2/2 ;Bax Fl/1 control mice (Bax 1/-BM ECs). BM c-kit1sca-11lin-(KSL) stem/progenitor cells were irradiated with 300 cGy and then placed in 7 day culture with Bax 2/2 BM ECs or Bax 1/-BM ECs. Culture with Bax 2/2 BM ECs yielded a 2000-fold increased number of BM KSL cells (p \ 0.05) compared to cultures with Bax 1/-ECs. This significant expansion of phenotypic BM stem/ progenitor cells corresponded to a 4-fold increase in CFU-S12 cells in the Bax 2/2 EC cultures vs. Bax 1/-EC cultures (p 5 0.01). Interestingly, following TBI, mice bearing Bak and Bax deletion in BM ECs displayed 18-fold increased concentration of epidermal growth factor (EGF) in BM serum compared to control mice (p 5 0.04), and inhibition of EGF signaling blocked the ability of Bax 2/2 BM ECs to support the expansion of BM HSCs following irradiation compared to culture with Bax 2/2 ECs alone (p 5 0.0002). Moreover, the addition of EGF to Bax 1/-BM ECs culture compared to culture with Bax 1/-BM ECs alone significantly increased the recovery of BM HSCs and progenitor cells following irradiation (p 5 0.0004), which was comparable to the recovery of BM HSCs and progenitor cells observed in Bax 2/2 BM EC cultures. These data demonstrate that therapeutic protection of the BM vascular niche protects BM HSCs from myelotoxic injury, and this protection is mediated by EGF action on BM HSCs. (HCT) . The widespread use of prophylactic oral triazoles has limitations of poor absorption, interindividual variability in metabolism, and hepatic toxicity. AmBisome (Amphotericin B liposomal complex) has a better safety profile than the parent drug, produces higher plasma and tissue concentrations, but long-term use is limited by the need for frequent intravenous administration. An alternative approach to prophylaxis is once a week (wk) high-dose AmBisome therapy.
SUPPORTIVE
Both animal and adult human data suggest that this dosing schedule can be effective. We have previously shown that this dosing regimen led to detectable and protective plasma levels of nonliposomal amphotericin on the seventh day in pediatric HCT patients (Mehta et al, 2006) .
Here we report our clinical experience of use of weekly high-dose (10mg/kg) AmBisome antifungal prophylaxis in high risk pediatric patients undergoing HCT. A total of 25 infants and children with various hematological and immune deficiency disorders undergoing HCT are reviewed retrospectively. The median age was 1.5 years (range 0.25-15). None of the patients had a history of previous fungal infection. All patients had normal renal function prior to starting weekly AmBisome and were on cyclosporine (CSA) for graft versus host disease prophylaxis.
Total length of therapy expanded over 7 to 54 wks (median 16 wks). Results are described in Table. Majority of the patients tolerated AmBisome infusion well, except rash, hypertension, increased work of breathing and hypotension in 2, 4, 1, and 1 patient respectively. Renal dysfunction (increase in Cr to twice the baseline value), was observed in 15 patients, at a median of 9 wks (range 1-31) of therapy. Of note, 2 patients sustained significant renal dysfunction, with Cr 4.9 and 5.1 (compared to baseline of 0.8 and 0.6 respectively) at wk 10 and 7 respectively, in the setting of septic shock and receiving gentamicin, vancomycin and CSA. None of the patients developed breakthrough fungal infection during weekly AmBisome therapy. 
* Cr -creatinine
We conclude that, high dose weekly AmBisome prophylaxis is safe and effective and provides a simple prophylaxis regimen that can be administered for long periods to infants and children on an outpatient basis. This approach has been used routinely at our institution in the past several years with continued excellent outcomes. 
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